Prevalence of Advanced Chronic Kidney Disease in Patients with Nonvalvular Atrial Fibrillation Hospitalized in Cardiology Departments

Objective To estimate the prevalence of chronic kidney disease (CKD) 3b-5 stages and the newly diagnosed sustained reduction in glomerular filtration rate (GFR) <30 ml/min/1.73 m2 in patients with atrial fibrillation (AF) in real clinical practice, as well as the features of their anticoagulant therapy. Materials and Methods Retrospectively, data of all discharge epicrisis from cardiological departments of five Moscow hospitals from June 1, 2016 to May 31, 2017 were analyzed. Patients over 18 years old with AF were enrolled. At the next stage, patients with CKD 3 b-5 st and newly diagnosed sustained reduction in GFR <30 ml/min/1.73 m2 (at least 2 measurements during hospitalization) were selected. Results Data of 9725 patients were analyzed, AF was diagnosed in 2983 (31 %) cases, of which a decreased GFR <45 ml/min/1.73 m2 was detected in 27 % (n = 794) cases. Among them, 349 (44 %) were diagnosed with CKD 3b st, 123 (15 %) with CKD 4 st, 44 (6 %) with CKD 5 st, 278 (35 %) had a newly diagnosed sustained reduction in GFR. In 63 % of patients with AF and GFR <45 ml/min/1.73 m2, anemia was diagnosed, 39 % of them had moderate and severe one. 711 (89 %) patients were prescribed anticoagulants, 53 % were assigned direct oral anticoagulants (DOACs). Patients with CKD 3 b st. more often rivaroxaban 15 mg (29 %) was prescribed, with CKD 4 and CKD 5-warfarin (48 % and 25 %, respectively), in patients with newly diagnosed sustained reduction in GFR <30 ml/min/1.73 m2- A pixaban 10 mg/day (16.2 %). Conclusion A quarter of patients with AF revealed a decreased GFR <45 ml/min/1.73 m2, half of them were recommended DOACs. 42 % of patients with GFR <30 ml/min/1.72 m2 were prescribed DOACs, 27 %-warfarin. Patients with CKD 5 st DOACs were not assigned; in half of cases, none of the anticoagulants was recommended. Most often, the dose of the prescribed anticoagulant was not counted according to GFR in patients with newly diagnosed sustained reduction in GFR